Form 4: Corcept Therapeutics Director Gregg Alton Granted 15,000 Stock Options

Corcept Therapeutics Inc. Director Gregg H. Alton was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.

Summary

• Gregg H. Alton, a Director of Corcept Therapeutics Inc. (CORT), was granted 15,000 stock options.
• The options have an exercise price of $72.27 per share.
• The grant date for these options is June 10, 2025.
• The options will vest ratably in equal installments on each monthly anniversary of June 10, 2025, over a one-year period.
• Vesting is contingent upon Mr. Alton's continued service on each monthly vesting date.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Mr. Alton beneficially owns 15,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Form 4 is a factual report of an insider transaction, the grant of options to a director is generally viewed positively as it aligns management's interests with shareholders and is a standard component of compensation, indicating continued commitment. It does not, however, provide new operational or financial performance insights.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, as the value of the options increases with the company's stock price.
• This equity grant serves as a form of compensation and retention for a key board member, indicating continued commitment to the company.

Risks

• The value of the stock options is subject to the future performance of Corcept Therapeutics' common stock; if the stock price does not exceed the exercise price of $72.27, the options may expire worthless.
• The vesting schedule requires continued service, meaning the director must remain on the board for the options to fully vest.

Future Outlook

This Form 4 filing primarily details an insider equity grant and does not provide a general future outlook or guidance for Corcept Therapeutics Inc. The future value of the options is tied to the company's stock performance over the next decade.

Industry Context

This filing is a routine disclosure of an insider equity grant, common in the biotechnology and pharmaceutical industries as a component of executive and director compensation. It does not provide insights into broader industry trends or competitive landscape beyond the specific company's compensation practices.

Related Party Transactions

• The grant of stock options to Gregg H. Alton, a director, constitutes a related party transaction as it involves the company and an insider.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial incentives with shareholder value creation, potentially leading to more focused efforts on increasing stock price.
• Employees (specifically Gregg H. Alton): This represents a significant component of his compensation, providing a long-term incentive tied to company performance.

Next Steps

• The stock options will vest monthly over a one-year period, starting June 10, 2025, subject to Gregg H. Alton's continued service.
• Gregg H. Alton may choose to exercise these options at any time after they vest and before their expiration date of June 10, 2035.

Key Dates

Keywords

Corcept Therapeutics, CORT, Gregg H. Alton, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant